Garth Lees-Rolfe
Director Financiero/CFO en INHIBIKASE THERAPEUTICS, INC. .
Fortuna: - $ al 31/05/2024
Perfil
Garth Lees-Rolfe is currently the Chief Financial Officer at Inhibikase Therapeutics, Inc. He previously worked as the Vice President-Finance at F-star Therapeutics, Inc. Mr. Lees-Rolfe completed his undergraduate degree at Queensland University of Technology.
Participaciones conocidas en empresas públicas
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
| 10/06/2024 | 0 ( -.--% ) | - $ | 31/05/2024 |
Cargos activos de Garth Lees-Rolfe
| Empresas | Cargo | Inicio |
|---|---|---|
| INHIBIKASE THERAPEUTICS, INC. | Director Financiero/CFO | 31/03/2024 |
Antiguos cargos conocidos de Garth Lees-Rolfe.
| Empresas | Cargo | Fin |
|---|---|---|
| F-STAR THERAPEUTICS, INC. | Corporate Officer/Principal | 01/11/2022 |
Formación de Garth Lees-Rolfe.
| Queensland University of Technology | Undergraduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas privadas | 2 |
|---|---|
| Inhibikase Therapeutics, Inc. | |
F-star Therapeutics, Inc.
 F-star Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology F-star Therapeutics, Inc. is a clinical-stage immuno-oncology company. It focuses on transforming the lives of patients with cancer through the development of tetravalent mAb2 bispecific antibodies. The firm's product candidate, FS118, simultaneously targets two immune checkpoint receptors, LAG-3 and PD-L1, to directly address known tumor evasion pathways. The company was founded on October 7, 2002 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
- Bolsa de valores
- Insiders
- Garth Lees-Rolfe
